<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Financings</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Financings for April 2, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Apollomics, Aprea, Bonus, Fibrobiologics, Innocan, Inspira, Newcelx, Venus Concept.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730082</guid>
      <pubDate>Thu, 02 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730082-financings-for-april-2-2026</link>
    </item>
    <item>
      <title>Ambrosia slurps up a $100M series B for its oral obesity drug pipeline</title>
      <description>
        <![CDATA[Ambrosia Biosciences Inc., named after the drink of the Greek gods, secured a $100 million series B to advance its preclinical pipeline of oral obesity drugs. The startup formed after Pfizer Inc. shuttered its Boulder, Colo.-based research facility that the pharma gained through its 2019 acquisition of Array Biopharma Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730076</guid>
      <pubDate>Thu, 02 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730076-ambrosia-slurps-up-a-100m-series-b-for-its-oral-obesity-drug-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Pills-bottle-scale-and-measuring-tape.webp?t=1704492123" type="image/jpeg" medium="image" fileSize="266968">
        <media:title type="plain">Pills, bottle, scale and-measuring tape</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for April 1, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Ambrosia, Diagens, Guided, Immunitybio, Scynexis, Soundable Health, Sub-Q Bionics, Tippingpoint, Volitionrx.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729985</guid>
      <pubDate>Wed, 01 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729985-financings-for-april-1-2026</link>
    </item>
    <item>
      <title>Tippingpoint raises seed financing to target epigenetic protein interfaces</title>
      <description>
        <![CDATA[Tippingpoint Biosciences Inc. has closed an oversubscribed $4.5 million seed financing. The company, spun out of a lab at University of California, San Francisco (UCSF), is advancing its novel drug discovery platform designed to identify first-in-class drugs to treat diseases related to dysfunctional DNA packaging (chromatin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730061</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730061-tippingpoint-raises-seed-financing-to-target-epigenetic-protein-interfaces</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Chromatin-compaction.webp?t=1775055876" type="image/jpeg" medium="image" fileSize="405741">
        <media:title type="plain">Chromatin compaction</media:title>
      </media:content>
    </item>
    <item>
      <title>Series B financing supports Ambrosia’s cardiometabolic pipeline</title>
      <description>
        <![CDATA[Ambrosia Biosciences Inc. has announced a $100 million oversubscribed series B financing intended to support progression of the company’s oral small-molecule GLP-1 candidate and other novel cardiometabolic programs into clinical development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730060</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730060-series-b-financing-supports-ambrosias-cardiometabolic-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-digital-dollar-sign.webp?t=1775054521" type="image/jpeg" medium="image" fileSize="639573">
        <media:title type="plain">Blue digital dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for March 31, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: 4DMedical, Alamar,&nbsp;Anaptysbio,<strong>&nbsp;</strong>Arch, Artelo, Centivax, First Tracks, Kailera, Oncomatryx.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729971</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729971-financings-for-march-31-2026</link>
    </item>
    <item>
      <title>Whoop secures $575M, with Abbott a strategic investor</title>
      <description>
        <![CDATA[Whoop Inc. secured $575 million in a series G funding round at a $10.1 billion valuation to advance its AI-powered wearable platform for personalized and preventive health care. Abbott Laboratories joined the round as a strategic investor, backing the company’s push to expand access to its device amid growing demand.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729965</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729965-whoop-secures-575m-with-abbott-a-strategic-investor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Whoop-band-3-31.webp?t=1774989701" type="image/jpeg" medium="image" fileSize="320371">
        <media:title type="plain">Whoop health and fitness band</media:title>
        <media:description type="plain">Whoop's wearable health and fitness band provides personalized insights across sleep, recovery, strain, fitness and longevity. Credit: Whoop Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Funding to advance Marvel’s MB-204 into clinic</title>
      <description>
        <![CDATA[Marvel Biosciences Corp., together with its wholly owned subsidiary Marvel Biotechnology Inc., has announced nondilutive funding from the Alberta Innovates CarE (AICE) market access program to support progression into the clinic and phase I testing of lead compound, MB-204. MB-204, a fluorinated derivative version of istradefylline, offers potential as a new approach totreating autism spectrum disorders and related conditions, addressing socio-behavioral symptoms through a differentiated mechanism.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730038</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730038-funding-to-advance-marvels-mb-204-into-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-with-puzzle-piece-removed.webp?t=1595012724" type="image/png" medium="image" fileSize="452654">
        <media:title type="plain">Brain with puzzle piece removed</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for March 30, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Apogee, Bioretec, Onkure, Precision Optics, Vor Bio, Zenas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729957</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729957-financings-for-march-30-2026</link>
    </item>
    <item>
      <title>Financings for March 27, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Icecure, Poxel.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729922</guid>
      <pubDate>Fri, 27 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729922-financings-for-march-27-2026</link>
    </item>
    <item>
      <title>Pinnacle raises an $89M series B for its oral peptide programs</title>
      <description>
        <![CDATA[Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730034</guid>
      <pubDate>Fri, 27 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730034-pinnacle-raises-an-89m-series-b-for-its-oral-peptide-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/finance-dollar-growth.webp?t=1638226495" type="image/png" medium="image" fileSize="416016">
        <media:title type="plain">Hand holding dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for March 26, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Apogee, Cellbricks, Gilgamesh, Harrow.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729908</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729908-financings-for-march-26-2026</link>
    </item>
    <item>
      <title>Idel raises $10.4M for intracellular pan-cancer drug delivery tech</title>
      <description>
        <![CDATA[Newco Idel Therapeutics GmbH has closed a €9 million (US$10.4 million) seed round to advance the development of a technology for delivery of cytotoxic drugs directly into the cytosol of tumor cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729904</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729904-idel-raises-104m-for-intracellular-pan-cancer-drug-delivery-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-under-magnifying-glass.webp?t=1611092780" type="image/png" medium="image" fileSize="453785">
        <media:title type="plain">Cancer cells under magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Pinnacle raises an $89M series B for its oral peptide programs</title>
      <description>
        <![CDATA[Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729903</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729903-pinnacle-raises-an-89m-series-b-for-its-oral-peptide-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/finance-dollar-growth.webp?t=1638226495" type="image/png" medium="image" fileSize="416016">
        <media:title type="plain">Hand holding dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Endogenex raises $50M for endoscopic diabetes treatment system</title>
      <description>
        <![CDATA[Endogenex Inc. has raised $50 million in an extension to its series C financing round to fund the completion of its pivotal Recet clinical study, which is evaluating the use of the company’s non-thermal pulsed electric field system for remodeling the duodenal tissue in adults with type 2 diabetes. The new capital will also be used to support the company's regulatory pathway toward U.S. FDA approval.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729902</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729902-endogenex-raises-50m-for-endoscopic-diabetes-treatment-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Money-financing.webp?t=1588371985" type="image/png" medium="image" fileSize="253228">
        <media:title type="plain">Hand holding gear, dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for March 25, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Amani, Karyopharm, Outlook, Research Alliance, Rybodyn, Sernova, Sol-Gel, Turn, Virchow.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729846</guid>
      <pubDate>Wed, 25 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729846-financings-for-march-25-2026</link>
    </item>
    <item>
      <title>Rybodyn raises funding to decode the dark proteome</title>
      <description>
        <![CDATA[Rybodyn Inc. has announced the initial close of a $10 million seed financing to support its work decoding the dark proteome using an AI-powered novel sequencing and discovery platform. The financing will accelerate the company’s transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729878</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729878-rybodyn-raises-funding-to-decode-the-dark-proteome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Health-research-body-molecules.webp?t=1743605757" type="image/jpeg" medium="image" fileSize="735256">
        <media:title type="plain">Art concept for medical research</media:title>
      </media:content>
    </item>
    <item>
      <title>Grant supports Epifrontier’s EPF-001 for β-globin disorders</title>
      <description>
        <![CDATA[Epifrontier Therapeutics Inc. has been awarded a grant of up to $32 million in nondilutive funding from the Japan Agency for Medical Research and Development (AMED) to advance the clinical development of EPF-001 (RK-701), a first-in-class G9a inhibitor being developed for sickle cell disease and β-thalassemia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729877</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729877-grant-supports-epifrontiers-epf-001-for-globin-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Red-blood-cell-DNA.webp?t=1623189044" type="image/png" medium="image" fileSize="588772">
        <media:title type="plain">Red blood cells, DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Excalipoint closes $68.7M seed round for cancer T-cell engagers </title>
      <description>
        <![CDATA[Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729898</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729898-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-gray-dollar-sign.webp?t=1773864630" type="image/jpeg" medium="image" fileSize="944348">
        <media:title type="plain">Blue-gray dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Imbiologics crosses $1B market cap with Kosdaq debut </title>
      <description>
        <![CDATA[Imbiologics Corp.’s market capitalization reached ₩1.5 trillion (US$1.02 billion) on its Kosdaq debut March 20, as the biotech seeks to become a leading antibody drugmaker for autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729897</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729897-imbiologics-crosses-1b-market-cap-with-kosdaq-debut</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Ha-Gyong-sik-CEO-Imbiologics-3-20.webp?t=1774038809" type="image/jpeg" medium="image" fileSize="550552">
        <media:title type="plain">Ha-Gyong-sik, CEO, Imbiologics</media:title>
        <media:description type="plain">Imbiologics CEO Ha-Gyong-sik at the company's IPO ceremony.</media:description>
      </media:content>
    </item>
    <item>
      <title>Financings for March 24, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Alligator, Diamyd, Hyperfine, Renovorx, Tempest.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729832</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729832-financings-for-march-24-2026</link>
    </item>
    <item>
      <title>Immutrin raises £65M series A to take another run at reversing amyloidosis</title>
      <description>
        <![CDATA[Newco Immutrin Ltd. has raised £65 million (US$86.9 million) in a series A to take its lead antibody program through to clinical proof of concept in transthyretin amyloid cardiomyopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729825</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729825-immutrin-raises-65m-series-a-to-take-another-run-at-reversing-amyloidosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-scientific-overlay.webp?t=1729781889" type="image/jpeg" medium="image" fileSize="394419">
        <media:title type="plain">Heart scientific overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Financing at Immutrin to advance antibody for ATTR cardiomyopathy</title>
      <description>
        <![CDATA[Immutrin Ltd. has successfully raised £65 million ($87 million) in series A financing to advance its lead asset through clinical proof of concept in ATTR cardiomyopathy. Immutrin’s novel antibody selectively binds to amyloid fibrils and is engineered to deplete amyloid deposits in tissue via a targeted and coordinated immune response.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729856</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729856-financing-at-immutrin-to-advance-antibody-for-attr-cardiomyopathy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardiology-heart-illustration.webp?t=1601070099" type="image/png" medium="image" fileSize="948393">
        <media:title type="plain">Colorful illustration of the heart</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for March 23, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Azitra, Bioxytran, Blue Water Acquisition, Bonus, Capsovision, Earendil, Hansa, Verily.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729818</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729818-financings-for-march-23-2026</link>
    </item>
    <item>
      <title>Laigo extends seed round as targeted protein degradation field gathers pace</title>
      <description>
        <![CDATA[Laigo Bio BV has extended its seed round to €17 million (US$19.8 million), after making progress with translating its novel E3 ubiquitin ligase targeted protein degradation technology toward the clinic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729812</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729812-laigo-extends-seed-round-as-targeted-protein-degradation-field-gathers-pace</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Euro-currency-symbol-white.webp?t=1669153720" type="image/png" medium="image" fileSize="307769">
        <media:title type="plain">White Euro symbol on blue background</media:title>
      </media:content>
    </item>
    <item>
      <title>Oryon emerges with autologous stem cell therapy for Parkinson’s</title>
      <description>
        <![CDATA[Oryon Cell Therapies, named after the Orion constellation used for navigation at night, emerged from stealth mode to announce a new round of funding and to present data from the phase Ib/IIa study of its neuron replacement therapy in patients with Parkinson’s disease at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729809</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729809-oryon-emerges-with-autologous-stem-cell-therapy-for-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Parkinson's-disease-illustration.webp?t=1643408215" type="image/png" medium="image" fileSize="519828">
        <media:title type="plain">Parkinson's disease illustration showing neurons containing alpha-synuclein</media:title>
      </media:content>
    </item>
    <item>
      <title>Grant supports Tessera’s genetic approaches to HIV cure</title>
      <description>
        <![CDATA[Tessera Therapeutics Inc. has received a grant from the Gates Foundation to support early-stage research exploring multiple genetic approaches aimed at developing a scalable cure for HIV. This research will evaluate several potential strategies leveraging Tessera’s Gene Writing platform to engineer immune cells in vivo.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729794</guid>
      <pubDate>Mon, 23 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729794-grant-supports-tesseras-genetic-approaches-to-hiv-cure</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Gene-therapy-illustration.webp?t=1608150701" type="image/png" medium="image" fileSize="436394">
        <media:title type="plain">DNA in drug capsules</media:title>
      </media:content>
    </item>
    <item>
      <title>Financings for March 20, 2026</title>
      <description>
        <![CDATA[Biopharma and med-tech companies raising money in public or private financings, including: Congruence, Reviva, Serina, TG.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729765</guid>
      <pubDate>Fri, 20 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729765-financings-for-march-20-2026</link>
    </item>
    <item>
      <title> Imbiologics crosses $1B market cap with Kosdaq debut </title>
      <description>
        <![CDATA[Imbiologics Corp.’s market capitalization reached ₩1.5 trillion (US$1.02 billion) on its Kosdaq debut March 20, as the biotech seeks to become a leading antibody drugmaker for autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729763</guid>
      <pubDate>Fri, 20 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729763-imbiologics-crosses-1b-market-cap-with-kosdaq-debut</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Ha-Gyong-sik-CEO-Imbiologics-3-20.webp?t=1774038809" type="image/jpeg" medium="image" fileSize="550552">
        <media:title type="plain">Ha-Gyong-sik, CEO, Imbiologics</media:title>
        <media:description type="plain">Imbiologics CEO Ha-Gyong-sik at the company's IPO ceremony.</media:description>
      </media:content>
    </item>
    <item>
      <title>Financing at Congruence to advance small-molecule correctors</title>
      <description>
        <![CDATA[Congruence Therapeutics Inc. has closed a $39.5 million financing to advance into its portfolio of small-molecule correctors for diseases of protein misfolding into the clinic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729776</guid>
      <pubDate>Fri, 20 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729776-financing-at-congruence-to-advance-small-molecule-correctors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-in-light-bulb-on-yellow-background.webp?t=1637008317" type="image/png" medium="image" fileSize="77494">
        <media:title type="plain">Dollar sign in light bulb on yellow background</media:title>
      </media:content>
    </item>
  </channel>
</rss>
